One vial with 5 ml concentrate contains 4 mg zoledronic acid (as monohydrate)
Zoledro-Denk prevents skeletal related events in patients with advanced malignancies involving bone fractures in patients with cancers, and treats tumor-induced hypercalcemia, osteoporosis (post-menopausal women and in men; even with a recent low-trauma hip fracture; also associated with long-term systemic glucocorticoid therapy) and Paget’s disease of the bone
Strong inhibition of osteoclastic bone resorption
Showed significant benefit in osteoporosis as well as reduction in mortality after hip fraction
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
3rd Party Cookies
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!